BHV3000-302 : Phase 3: Double-Blind, Randomized, Placebo-Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) for the Acute Treatment of Migraine
Phase of Trial: Phase III
Latest Information Update: 18 Oct 2017
At a glance
- Drugs Rimegepant (Primary)
- Indications Migraine
- Focus Therapeutic Use
- Sponsors Biohaven Pharmaceutical Holding Company
- 11 Oct 2017 Planned number of patients changed from 850 to 1200.
- 11 Sep 2017 According to a Biohaven Pharmaceutical Holding Company media release, over 1,200 subjects have been enrolled and 750 subjects have been randomized to treatment across the two phase III trials combined (studies BHV3000-301 and BHV3000-302).
- 14 Aug 2017 According to a Biohaven Pharmaceutical Holding Company media release, dosing has commenced in this trial.